Research programme: Candida albicans vaccine - Roche/TheraCarb
Latest Information Update: 05 Aug 2013
At a glance
- Originator TheraCarb
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Candidiasis
Most Recent Events
- 30 Nov 2010 Discontinued - Preclinical for Candidiasis in Canada (unspecified route)
- 30 Nov 2009 No development reported - Preclinical for Candidiasis in Canada (unspecified route)
- 26 Jun 2007 BioVeris Corporation has been acquired and merged into Roche